{"id":"https://openalex.org/W3089094196","doi":"https://doi.org/10.1016/s2352-3026(20)30290-8","title":"Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact","display_name":"Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact","publication_year":2020,"publication_date":"2020-09-22","ids":{"openalex":"https://openalex.org/W3089094196","doi":"https://doi.org/10.1016/s2352-3026(20)30290-8","mag":"3089094196","pmid":"https://pubmed.ncbi.nlm.nih.gov/32976744"},"language":"en","primary_location":{"id":"doi:10.1016/s2352-3026(20)30290-8","doi":"https://doi.org/10.1016/s2352-3026(20)30290-8","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2352-3026(20)30290-8","pdf_url":null,"source":{"id":"https://openalex.org/S2531671668","display_name":"The Lancet Haematology","issn_l":"2352-3026","issn":["2352-3026","2451-9960"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet Haematology","raw_type":"journal-article"},"volume":null,"type":"letter","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088459737","display_name":"Stephen Douglas Smith","orcid":"https://orcid.org/0000-0001-5354-7593","observed_orcids":["https://orcid.org/0000-0001-5354-7593"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Stephen D Smith","raw_affiliation_strings":["Division of Medical Oncology and Fred Hutchinson Cancer Research Center, Clinical Research Division, University of Washington, Seattle, WA 98109, USA. Electronic address: ssmith50@seattlecca.org","Division of Medical Oncology and Fred Hutchinson Cancer Research Center, Clinical Research Division, University of Washington, Seattle, WA 98109, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medical Oncology and Fred Hutchinson Cancer Research Center, Clinical Research Division, University of Washington, Seattle, WA 98109, USA. Electronic address: ssmith50@seattlecca.org","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]},{"raw_affiliation_string":"Division of Medical Oncology and Fred Hutchinson Cancer Research Center, Clinical Research Division, University of Washington, Seattle, WA 98109, USA","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004025497","display_name":"Ajay K. Gopal","orcid":"https://orcid.org/0000-0003-3023-6834","observed_orcids":["https://orcid.org/0000-0003-3023-6834"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ajay K Gopal","raw_affiliation_strings":["Division of Medical Oncology and Fred Hutchinson Cancer Research Center, Clinical Research Division, University of Washington, Seattle, WA 98109, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medical Oncology and Fred Hutchinson Cancer Research Center, Clinical Research Division, University of Washington, Seattle, WA 98109, USA","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5088459737"],"corresponding_institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"],"apc_list":{"value":5000,"currency":"USD","value_usd":5000},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"7","issue":"10","first_page":"e707","last_page":"e707"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9775000214576721,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9775000214576721,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0038999998942017555,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/selinexor","display_name":"selinexor","score":0.9980000257492065},{"id":"https://openalex.org/keywords/relapsed-refractory-diffuse-large-b-cell-lymphoma","display_name":"relapsed/refractory diffuse large B-cell lymphoma","score":0.9869999885559082},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7670000195503235},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.4320000112056732},{"id":"https://openalex.org/keywords/subgroup-selection","display_name":"subgroup selection","score":0.38600000739097595}],"concepts":[{"id":"https://openalex.org/C2778559949","wikidata":"https://www.wikidata.org/wiki/Q2626074","display_name":"Diffuse large B-cell lymphoma","level":3,"score":0.7543336153030396},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7516385316848755},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.6608994007110596},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5590559244155884},{"id":"https://openalex.org/C2780790343","wikidata":"https://www.wikidata.org/wiki/Q5090610","display_name":"Chemoimmunotherapy","level":4,"score":0.5318400859832764},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4868561625480652},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4783705770969391},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4333973228931427},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4226565957069397},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.20839941501617432},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006834","descriptor_name":"Hydrazines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016403","descriptor_name":"Lymphoma, Large B-Cell, Diffuse","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D016477","descriptor_name":"Artifacts","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/s2352-3026(20)30290-8","doi":"https://doi.org/10.1016/s2352-3026(20)30290-8","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2352-3026(20)30290-8","pdf_url":null,"source":{"id":"https://openalex.org/S2531671668","display_name":"The Lancet Haematology","issn_l":"2352-3026","issn":["2352-3026","2451-9960"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet Haematology","raw_type":"journal-article"},{"id":"pmid:32976744","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32976744","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet. Haematology","raw_type":"Letter"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9911999702453613,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307771","display_name":"Bayer","ror":"https://ror.org/04hmn8g73"},{"id":"https://openalex.org/F4320307776","display_name":"Merck","ror":"https://ror.org/02891sr49"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320312415","display_name":"Portola Pharmaceuticals","ror":"https://ror.org/00r8a6s58"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":4,"referenced_works":["https://openalex.org/W2117460825","https://openalex.org/W2984927918","https://openalex.org/W3037697670","https://openalex.org/W3176363517"],"related_works":["https://openalex.org/W3088746712","https://openalex.org/W3037697670","https://openalex.org/W3094677503","https://openalex.org/W6977658391","https://openalex.org/W4200378581","https://openalex.org/W3186039091","https://openalex.org/W2901204777","https://openalex.org/W3168066833","https://openalex.org/W4210397531","https://openalex.org/W2987020211"],"abstract_inverted_index":null,"counts_by_year":[{"year":2021,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-10-01T00:00:00"}